Market capitalization | $612.00m |
Enterprise Value | $555.59m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.87 |
P/S ratio (TTM) P/S ratio | 3.17 |
P/B ratio (TTM) P/B ratio | 0.84 |
Revenue growth (TTM) Revenue growth | -28.47% |
Revenue (TTM) Revenue | $193.26m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a 23andMe Holding Co - Ordinary Shares - Class A forecast:
2 Analysts have issued a 23andMe Holding Co - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 193 193 |
28%
28%
|
|
Gross Profit | 64 64 |
28%
28%
|
|
EBITDA | -245 -245 |
22%
22%
|
EBIT (Operating Income) EBIT | -271 -271 |
22%
22%
|
Net Profit | -615 -615 |
83%
83%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.
Head office | United States |
CEO | Anne Wojcicki |
Employees | 582 |
Founded | 2006 |
Website | www.23andme.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.